P. Edman

Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia

E. Kimby, A. Österborg, J. Lundin, 2004, Leukemia.